Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Reneo Pharmaceuticals ( (RPHM) ) has issued an announcement.
Reneo Pharmaceuticals, Inc. is undergoing a significant transformation through a merger with OnKure, Inc., while also halting its historical drug development activities. This strategic shift has led to the termination of Ashley F. Hall, J.D., the Chief Development Officer, effective September 13, 2024. As part of the departure, Hall is set to receive severance benefits as outlined in the company’s existing severance benefit plan.
For detailed information about RPHM stock, go to TipRanks’ Stock Analysis page.